title: Radioiodine treatment after surgery for differentiated thyroid cancer: a reasonable option.
authors.affiliation: Department of Nuclear Medicine, Cochin University Hospital, Paris 5 René Descartes University, Paris, France.
authors.forename: Jérôme
authors.initials: J
authors.lastname: Clerc
authors.affiliation: Department of Nuclear Medicine, University Hospital Marburg, Marburg, Germany.
authors.forename: Frederik A
authors.initials: FA
authors.lastname: Verburg
authors.affiliation: Nuclear Medicine/Radiology, University of Michigan, Ann Arbor, USA.
authors.forename: Anca M
authors.initials: AM
authors.lastname: Avram
authors.affiliation: Department of Nuclear Medicine and Thyroid Centre, Oncology Institute of Southern Switzerland, Bellinzona, Switzerland.
authors.forename: Luca
authors.initials: L
authors.lastname: Giovanella
authors.affiliation: Nuclear Medicine, Haut-Lévêque University Hospital, Bordeaux, France.
authors.forename: Elif
authors.initials: E
authors.lastname: Hindié
authors.affiliation: Department of Nuclear Medicine, European Center for Research in Medical Imaging, La Timone University Hospital, Aix-Marseille University, 264 rue Saint-Pierre, 13385, Marseille, France. david.taieb@ap-hm.fr.
authors.forename: David
authors.initials: D
authors.lastname: Taïeb
mesh_terms: D003657:Decision Making; D006801:Humans; D007457:Iodine Radioisotopes / Q000008:administration & dosage / Q000627:therapeutic use*; D011184:Postoperative Period; D018570:Risk Assessment; D013954:Thyroglobulin / Q000378:metabolism; D013964:Thyroid Neoplasms / Q000378:metabolism / Q000473:pathology / Q000532:radiotherapy* / Q000601:surgery*
chemical_list: D007457:Iodine Radioisotopes; D013954:Thyroglobulin